On Thursday, IsoRay, Inc. (NYSEMKT:ISR)’s shares declined -35.26% to $2.02.
IsoRay, Inc. (ISR) declared that a number of industry leaders talk about the successes achieved by their patients in a variety of body sites being treated with IsoRay’s Cesium-131 internal radiation (brachytherapy) cancer seeds at the “Advances in Brachytherapy” symposium, held at Weill Cornell on Friday and Saturday.
soRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States.
Lumber Liquidators Holdings Inc (NYSE:LL)’s shares dropped -16.50% to $21.10.
Lumber Liquidators Holdings Inc (LL) declared financial results for the first quarter ended March 31, 2015.
First Quarter Results
Net sales in the first quarter of 2015 were $260.0 million, an enhance of 5.6% from the first quarter of 2014 and a compound annual growth rate of 6.2% over the first quarter of 2013. Net sales in the month of March 2015 were $89.4 million, a decrease of 12.8% in comparison to March 2014. Net sales trends in March 2015 were significantly weaker than trends in January and February 2015, as net sales were negatively influenced by unfavorable allegations surrounding the product quality of the Company’s laminates sourced from China. The Company opened four new stores during the first quarter of 2015 and was operating 356 locations at March 31, 2015.
Lumber Liquidators Holdings, Inc., together with its auxiliaries, operates as a multi-channel specialty retailer of hardwood flooring, and hardwood flooring enhancements and accessories.
At the end of Thursday’s trade, Bruker Corporation (NASDAQ:BRKR)‘s shares dipped -14.27% to $19.04.
Bruker Corporation (BRKR) declared that on May 19, 2015, Mr. Charles F. Wagner, Jr., Executive Vice President and the Chief Financial Officer (CFO) of Bruker since July 2012, presented his resignation, effective June 12, 2015, in order to pursue other interests. Mr. Wagner has informed the Company that he has accepted a position as Chief Financial Officer of Ortho-Clinical Diagnostics, Inc., and will commence service in that position in late June 2015. Mr. Wagner’s resignation is not the result of any dispute or disagreement with the Company or any matter regarding the Company’s accounting practices or financial statements.
Bruker Corporation, together with its auxiliaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies.
Lpath, Inc. (NASDAQ:LPTN), ended its Thursday’s trading session with -13.94% loss, and closed at $0.297.
Lpath, Inc. (LPTN) declared that its multicenter, Phase 2 “Nexus” clinical trial evaluating iSONEP™ in patients with wet age-related macular degeneration (wet AMD) did not meet its primary or key secondary endpoints. Wet AMD patients who had not responded adequately to existing anti-vascular endothelial growth factor (VEGF) therapies counting Lucentis®, Avastin® and Eylea® did not show any statistically noteworthy improvement in visual acuity when treated with iSONEP as an adjunctive or monotherapy.
Lpath, Inc., a biotechnology company, focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
